This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tackey, E Articles by Illei, G G Search for Related Content PubMed PubMed Citation Articles by Tackey, E Articles by Illei, G G Social Bookmarking                         What's this?

Rationale for interleukin-6 blockade in systemic lupus erythematosus

Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA

P E Lipsky

Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA

G G Illei

Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, USA, illeig{at}mail.nih.gov

Interleukin-6 (IL-6) is a pleiotropic cytokine with a wide range of biological activities that plays an important role in immune regulation and inflammation. Among other actions, it induces terminal differentiation of B lymphocytes into antibody-forming cells and the differentiation of T cells into effector cells. IL-6 also has multiple potent proinflammatory effects. An associationbetween IL-6 and lupus was demonstrated in murine models of SLE and blocking IL-6 improved lupus in all models tested. Data from several studies suggest that IL-6 plays a critical role in the B cell hyperactivity and immunopathology of human SLE, and may have a direct role in mediating tissue damage. Based on these data, we propose that blocking the effect of IL-6 in humans may improve lupus by interacting with the autoinflammatory process both systemically and locally.

Key Words: autoimmunity • biologic therapy • cytokines • experimental treatment

Lupus, Vol. 13, No. 5, 339-343 (2004)
DOI: 10.1191/0961203304lu1023oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Richez, K. Yasuda, R. G. Bonegio, A. A. Watkins, T. Aprahamian, P. Busto, R. J. Richards, C. L. Liu, R. Cheung, P. J. Utz, et al. IFN Regulatory Factor 5 Is Required for Disease Development in the Fc{gamma}RIIB-/-Yaa and Fc{gamma}RIIB-/- Mouse Models of Systemic Lupus Erythematosus J. Immunol., January 15, 2010; 184(2): 796 - 806. [Abstract] [Full Text] [PDF]

				H. CASH, M. RELLE, J. MENKE, C. BROCHHAUSEN, S. A. JONES, N. TOPLEY, P. R. GALLE, and A. SCHWARTING Interleukin 6 (IL-6) Deficiency Delays Lupus Nephritis in MRL-Faslpr Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in Systemic Lupus Erythematosus J Rheumatol, January 1, 2010; 37(1): 60 - 70. [Abstract] [Full Text] [PDF]

				B. H. Rovin and X. Zhang Biomarkers for Lupus Nephritis: The Quest Continues Clin. J. Am. Soc. Nephrol., November 1, 2009; 4(11): 1858 - 1865. [Abstract] [Full Text] [PDF]

				B. H. Rovin, A. M. McKinley, and D. J. Birmingham Can We Personalize Treatment for Kidney Diseases? Clin. J. Am. Soc. Nephrol., October 1, 2009; 4(10): 1670 - 1676. [Abstract] [Full Text] [PDF]

				M. R. Gilbert, D. G. Carnathan, P. C. Cogswell, L. Lin, A. S. Baldwin Jr, and B. J. Vilen Dendritic Cells from Lupus-Prone Mice Are Defective in Repressing Immunoglobulin Secretion J. Immunol., April 15, 2007; 178(8): 4803 - 4810. [Abstract] [Full Text] [PDF]

				M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci Interleukin-6 in Aging and Chronic Disease: A Magnificent Pathway J Gerontol A Biol Sci Med Sci, June 1, 2006; 61(6): 575 - 584. [Abstract] [Full Text] [PDF]

				A Wozniacka, A Lesiak, J Narbutt, D P McCauliffe, and A Sysa-Jedrzejowska Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients Lupus, May 1, 2006; 15(5): 268 - 275. [Abstract] [PDF]

				E. Savarese, O.-w. Chae, S. Trowitzsch, G. Weber, B. Kastner, S. Akira, H. Wagner, R. M. Schmid, S. Bauer, and A. Krug U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7 Blood, April 15, 2006; 107(8): 3229 - 3234. [Abstract] [Full Text] [PDF]

				S. V. Navarra Immune therapy of lupus: what is on the horizon? Nephrol. Dial. Transplant., March 1, 2006; 21(3): 579 - 581. [Full Text] [PDF]

				B. Chen, S. Tsui, and T. J. Smith IL-1{beta} Induces IL-6 Expression in Human Orbital Fibroblasts: Identification of an Anatomic-Site Specific Phenotypic Attribute Relevant to Thyroid-Associated Ophthalmopathy J. Immunol., July 15, 2005; 175(2): 1310 - 1319. [Abstract] [Full Text] [PDF]

				S Vasoo and G R. Hughes Theory, targets and therapy in systemic lupus erythematosus Lupus, March 1, 2005; 14(3): 181 - 188. [Abstract] [PDF]